Beverly Hills, CALIFORNIA1 Active Studies

Mantle Cell Lymphoma Clinical Trials in Beverly Hills, CALIFORNIA

Find 1 actively recruiting mantle cell lymphoma clinical trials in Beverly Hills, CALIFORNIA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
421
Enrolling

Recruiting Mantle Cell Lymphoma Studies in Beverly Hills

About Mantle Cell Lymphoma Clinical Trials in Beverly Hills

Mantle cell lymphoma (MCL) is a rare, aggressive type of non-Hodgkin lymphoma that develops from B-cells in the mantle zone of lymph nodes. It accounts for about 5-7% of all NHL cases. Treatment includes combination chemotherapy, targeted therapy, and stem cell transplant.

There are currently 1 mantle cell lymphoma clinical trials recruiting participants in Beverly Hills, CALIFORNIA. These studies are seeking a combined 421 participants. Research is being sponsored by Alliance for Clinical Trials in Oncology. Clinical trial participation is free and participants receive study-related medical care at no cost.

Mantle Cell Lymphoma Clinical Trials in Beverly Hills — FAQ

Are there mantle cell lymphoma clinical trials in Beverly Hills?

Yes, there are 1 mantle cell lymphoma clinical trials currently recruiting in Beverly Hills, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Beverly Hills?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Beverly Hills research site will contact you about next steps.

Are clinical trials in Beverly Hills free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Beverly Hills studies also compensate for your time and travel.

What mantle cell lymphoma treatments are being tested?

The 1 active trials in Beverly Hills are testing new therapies including novel drugs, biologics, and treatment approaches for mantle cell lymphoma.

Data updated March 2, 2026 from ClinicalTrials.gov